IDRA-21

IDRA-21

Detailed Product Description

Nootropic Supplement Smart Drug IDRA 21 for Memory Improvement

Quick Detail

Product Name IDRA 21

CAS 22503-72-6

MF C8H9ClN2O2S

MW 232.69

Purity 99%

BP 405.1°C at 760 mmHg

FP 198.8°C

Density 1.394g/cm3

Grade Pharmaceutical Grade

Appearance White Powder

IDRA-21 is a relatively new nootropic compound. It works as an ampakine stimulant drug and is currently being researched in regards to its effects in memory improvement, cognitive enhancement, stimulation, and reversing cognitive deficits.

Powerful Drug

IDRA-21 is an ampakine drug derived from benzothiadiazine and a positive allosteric modulator of glutamate AMPA receptors. IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10-30 times more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine, and produces sustained effects lasting for up to 48 hours after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.

IDRA-21 is an ampakine drug and a benzothiadiazine derivative. IDRA-21 is a chiral molecule, with (+)-IDRA-21 being the active form.

IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10-30 times more potent than aniracetam in reversing cognitive deficits, and produces sustained effects lasting for up to 48 hours after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.

IDRA-21 does not produce neurotoxicity under normal conditions, although it may worsen neuronal damage following global ischemia after stroke or seizures.

In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent than CX-546.[8] Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed,but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.

In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent than CX-546. Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.

IDRA-21 Benefits

1. Increase in cognition.

2. Increase Task Accuracy

3. Increases in Short Term Memory

4. Potential Therapeutic Effects On Schizophrenia

5. Potental Therapeutic Effects On Depression

6. Neuroprotection

IDRA-21 Mechanism Of Action

As an Ampakine, IDRA-21 works by modulating AMPA receptors in the brain. it may prevent AMPA receptor desensitization, specifically IDRA-21 binds to the allosteric site of the AMPA receptor and induce positive modulation, this is sometimes called allosteric activation.

This property enhances long-term potentiation, especially within the hippocampus and may thus have beneficial therapeutic effects. This research could imply that IDRA-21 facilitates treatment of AMPA-related learning disabilities or enhancing intelligence in those without any learning disabilities.

In animal studies, IDRA-21 showed extremely long-lasting nootropic effects in improved learning and memory for up to 48 hours with a single dose. IDRA-21 showed to be up to ten times more powerful than the similar supplement aniracetam.

IDRA-21 Safety and Side Effects

IDRA-21 is a potent Ampakine. AMPA activation has been shown to exacerbate hippocampal neural damage. IDRA-21 when administered with glutamate killed rat hippocampal neurons through AMPA excitoxicity. This is potentially dangerous in patients with conditions that excessively activate AMPA such as strokes and seizures.

In another study, the dosages of IDRA-21 that induced neurotoxicity were several orders of magnitude higher than the doses that achieved cognitive enhancement in rats and monkeys, leading the researchers to conclude that IDRA-21 has relatively low neurotoxicity in therapeutic doses.